NVO250117C240000
- 12.20
- 0.000.00%
Novo-Nordisk A/S Newsroom
Obesity Drug Developer Metsera Sets Terms for $275M IPO
Market Whales and Their Recent Bets on NVO Options
European Equities Traded in the US as American Depositary Receipts Tread Water in Monday Trading
Akero Therapeutics Stock Doubles on Liver Data -- Barrons.com
Novo Nordisk's Amycretin Data Highly Encouraging -- Market Talk
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Express News | Novo-Nordisk A/S plans to continue providing free insulin to patients in need.
Veru Down 46% Despite Data for Drug Preserving Lean Body Mass in Wegovy Users
European Pharma Companies to Report 4Q Results With U.S Policy Uncertainty in Focus -- Sector Preview
Barclays Keeps Novo Nordisk at Overweight After Upbeat Trial Results for Weight Loss Drug
This Wegovy User Spent $5,000 on a New Wardrobe After Losing 80 Pounds - and She's Not Alone
Why Novo Nordisk A/S (NVO) Surged on Friday
Is Novo Nordisk (NVO) the Best Stock to Buy and Hold for 2025?
Donald Trump in Heated Phone Call With Danish Prime Minister Over Greenland: Report
Health Care Up on Novo Nordisk Optimism -- Health Care Roundup
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
Novo-Nordisk A/S Options Spot-On: On January 24th, 123.8K Contracts Were Traded, With 341.03K Open Interest
On January 24th ET, $Novo-Nordisk A/S(NVO.US)$ had active options trading, with a total trading volume of 123.8K options for the day, of which put options accounted for 45.36% of the total
US Equities Markets Fall Friday as Investors Assess Inflation, Consumer Sentiment
Sector Update: Health Care Stocks Advance Late Afternoon
Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?